Please ensure Javascript is enabled for purposes of website accessibility

Is This Diabetes Drug Stock in Jeopardy?

By Dave Williamson - Sep 14, 2013 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And the larger implications of the Express Scripts decision.

The news that pharmacy-benefits manager Express Scripts is ditching the world's biggest diabetes-focused company came as a surprise. It will no longer use Novo Nordisk's Victoza, or any of its diabetes products, including insulin. The implications are threefold.

This is a clear blow for Novo Nordisk, as it will negatively affect sales of not only Victoza but also Novolog, and it may be hard for Novo to hit earnings guidance. It's also interesting that Express Scripts would go with a less premium product than Victoza -- it's an indication that it may be using its post-merger weight to negotiate better deals for branded products, given Victoza's popularity. Finally, this is a clear win for Eli Lilly, and it validates management's decision to become a diabetes powerhouse, even if a lot of its offerings are still in drug development.

In this video, health-care analyst David Williamson discusses what these events mean for investors in Novo Nordisk, Eli Lilly, and Express Scripts, along with the broader implications of this decision. 

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Eli Lilly, Express Scripts, and Merck. Follow David on Twitter: @MotleyDavid.

The Motley Fool recommends and owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.02 (2.35%) $2.09
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
NVO
$107.50 (-0.65%) $0.71
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$308.08 (2.63%) $7.89
Express Scripts Holding Company Stock Quote
Express Scripts Holding Company
ESRX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.